Buy & Sell Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) – Bio-Rad Laboratories, Inc. Class A Common Stock Price Today
Aura AI Summary
Key Stats
- $7.45BMarket Cap
- HealthSector
- -20.92%3M Drawdown
- $7.27BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 52 daysTypical Hold Time
Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) is currently valued at a market capitalization of $7.45B, with an enterprise value of $7.27B. Over the past 52 weeks, Bio-Rad Laboratories, Inc. Class A Common Stock has traded between a low of $216.56 and a high of $339.75, highlighting its annual price range. Over the past three months, Bio-Rad Laboratories, Inc. Class A Common Stock has recorded a drawdown of -20.92%, reflecting recent price volatility. On average, investors hold Bio-Rad Laboratories, Inc. Class A Common Stock for approximately 52 days, indicating typical investor behavior on the platform.
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Most Recent News
BC launches Outdoor Sector Coalition to boost economy, health, and conservation of its outdoors.
A coalition of over 2,000 organizations in British Columbia has formed to support the province's outdoor sector, which is a $17 billion industry employing 80,000 people. The coalition aims to enhance health benefits, support outdoor businesses, and p...
ESR1-mutated metastatic breast cancer market to grow 9.6% CAGR with new oral SERDs and targeted therapies.
The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies ...
Exosens doubles cooled infrared camera production to meet rising demand in counter-drone systems.
Exosens plans to double its production capacity for cooled infrared cameras in 2026 to meet growing global demand, especially for long-range surveillance and counter-drone applications. These cameras, made in France, are critical for detecting drone ...